Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $739000.0.

  • Entrada Therapeutics' Amortizatization of Intangibles fell 7699.97% to $739000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 4169.3%. This contributed to the annual value of $10.0 million for FY2024, which is 7335.18% up from last year.
  • Per Entrada Therapeutics' latest filing, its Amortizatization of Intangibles stood at $739000.0 for Q3 2025, which was down 7699.97% from $961000.0 recorded in Q2 2025.
  • Entrada Therapeutics' Amortizatization of Intangibles' 5-year high stood at $3.2 million during Q3 2024, with a 5-year trough of -$145000.0 in Q2 2022.
  • Moreover, its 4-year median value for Amortizatization of Intangibles was $1.3 million (2025), whereas its average is $1.2 million.
  • In the last 5 years, Entrada Therapeutics' Amortizatization of Intangibles skyrocketed by 568750.0% in 2023 and then plummeted by 7699.97% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Amortizatization of Intangibles (Quarter) stood at $104000.0 in 2022, then surged by 1822.12% to $2.0 million in 2023, then grew by 25.41% to $2.5 million in 2024, then tumbled by 70.52% to $739000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $739000.0 for Q3 2025, versus $961000.0 for Q2 2025 and $1.3 million for Q1 2025.